Does ENTRECTINIB Cause Neoplasm malignant? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Neoplasm malignant have been filed in association with ENTRECTINIB (Rozlytrek). This represents 0.8% of all adverse event reports for ENTRECTINIB.
12
Reports of Neoplasm malignant with ENTRECTINIB
0.8%
of all ENTRECTINIB reports
3
Deaths
4
Hospitalizations
How Dangerous Is Neoplasm malignant From ENTRECTINIB?
Of the 12 reports, 3 (25.0%) resulted in death, 4 (33.3%) required hospitalization.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENTRECTINIB. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does ENTRECTINIB Cause?
Dizziness (143)
Off label use (137)
Death (126)
Disease progression (105)
Taste disorder (68)
No adverse event (65)
Constipation (60)
Fatigue (60)
Drug ineffective (58)
Blood creatinine increased (57)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which ENTRECTINIB Alternatives Have Lower Neoplasm malignant Risk?
ENTRECTINIB vs ENZALUTAMIDE
ENTRECTINIB vs EPCORITAMAB
ENTRECTINIB vs EPCORITAMAB-BYSP
ENTRECTINIB vs EPERISONE
ENTRECTINIB vs EPHEDRINE